Skip to content

Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)

Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02774928
Enrollment
150
Registered
2016-05-17
Start date
2016-06-30
Completion date
2017-05-31
Last updated
2016-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary Hypertension, COPD, ILD, OSA

Brief summary

Development of pulmonary hypertension (PH) in chronic lung diseases has both functional and prognostic implications . PH in Lung diseases is usually mild to moderate with preserved cardiac output, and evolves slowly alongside the progression of lung disease and hypoxemia . However, a minority of patients develop severe PH with elevations in pulmonary artery pressure that have been described as ''out of proportion'' to the underlying disease . The aim of this study is to compare the characteristics and outcomes of consecutive patients with PH-due to lung diseases diagnosed at our specialist referral center over a 1-year period.

Detailed description

Development of pulmonary hypertension (PH) in chronic lung diseases has both functional and prognostic implications . PH in Lung diseases is usually mild to moderate with preserved cardiac output, and evolves slowly alongside the progression of lung disease and hypoxemia . However, a minority of patients develop severe PH with elevations in pulmonary artery pressure that have been described as ''out of proportion'' to the underlying disease . Hypotheses for the etiology of this phenotype include greater susceptibility to alveolar hypoxia and/or tobacco smoke , destruction of the capillary vascular bed , inflammatory factors initiating remodeling of the pulmonary vascular bed or the coexistence of idiopathic pulmonary arterial hypertension (IPAH) in patients with lung disease . Severe PH-lung disease has been arbitrarily defined by a resting mean pulmonary artery pressure (PAP) ≥35 mmHg by RHC . The high and increasing prevalence of chronic lung diseases and the substantial consequences of developing severe PH have generated increasing interest in PH-lung diseases. Pulmonary vascular research unit at Chest department at Kasr-Alani school of Medicine delivers regional, adult PH service to a population with a chronic lung disease. The aim of this study is to compare the characteristics and outcomes of consecutive patients with PH-due to lung diseases diagnosed at our specialist referral center over a 1-year period. Patients diagnosed as chronic lung diseases( COPD,ILD,OSA,Sarcoidosis) will be recruited from out-patient's clinics & inpatients wards of Internal medicine & Chest departments, Kasr Al-ainy hospital (from June 2016 to May 2015) A written informed consent matching with Helsinki declaration will be taken from all patients. 2.2 Study methods: All the enrolled patients will go through the following basically: 1. Detailed standard Demographic & clinical parameters. 2. Assessment of exercise tolerance (6 MWD & WHO functional capacity) 3. Assessment of pulmonary function by PFTs. 4. ECG: (Right ventricular strain,Right axis deviation,Right bundle branch block,& Left side changes 0 5. Echocardiographic evaluation for PAH: ( Right atrial area ,Right ventricular area ,Tricuspid regurgitant jet velocity (TR) ,Tricuspid annular plane systolic excursion) 6. Radiography: including chest X-ray, HRCT chest, V/Q scan& CT angiography if needed 10\. RT sided heart catheterization: * mPAP * PCWP * PVR * CARDIAC INDEX 11. Statistical analysis: …….. The subjects will be classified according to RHC into either * Non PAH groups mPAP ≤ 21mmHG * PAH mPAP≥ 25 mmHG: * Severe PH-lung diseases mPAP ≥ 35 mmgh

Interventions

None listed

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. COPD diagnosed according to Gold 2015 2. Interstial lung diseases 3. Obstructive Sleep Apnea 4. sarcoidosis

Exclusion criteria

* Bronchogenic carcinoma

Design outcomes

Primary

MeasureTime frame
prevalence of PH1 year

Countries

Egypt

Contacts

Primary ContactMostafa I Elshazly, MD
elshazly66@hotmail.com00201001272020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026